ClinicalTrials.gg
RecruitingNCT06196086Updated Jan 9, 2024

Myocardial Stiffness Evaluation in Patients With Heart Failure With Preserved Ejection Fraction

An observational study in Heart Failure With Preserved Ejection Fraction, sponsored by Haiyan Wang. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-09.

Sponsored by Haiyan Wang · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
438
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 377 studies in Heart Failure with a site in China — 162 open to participants now, 182 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
73rd of 130
438 · median 554
Started
2023
with 42 others
Observational
130 of 377
64 open now
Primary completion
2026-12
later than 80 of 181 live
Registered
231st of 377
by date

Among the 377 studies in Heart Failure with a site in China, this one is the 73rd largest by planned enrollment of the 130 observational ones that give a count, is one of 43 that started in 2023, is one of 130 observational ones, reaches primary completion later than 80 of the 181 other live ones, and was the 231st registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 377 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 377 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

The goal of this observational study is to evaluating myocardial stiffness in patients with heart failure with preserved ejection fraction (HFpEF) by intrinsic wave velocity propagation (IVP). The main questions it aims to answer are:

  • Whether myocardial stiffness assessed by IVP in patients with HFpEF Increased.
  • Whether IVP is related to the cardiac structure and function in patients with HFpEF.
  • What are the risk factors that may be associated with heart failure rehospitalization in patients with HFpEF?
  • Whether increased myocardial stiffness is a risk factor for heart failure rehospitalization.

Participants will undergo transthoracic echocardiography to obtain conventional ultrasound parameters, and software post-processing analysis to obtained two-dimensional strain parameters and IVP, as well as general clinical data and laboratory test results. Clinical followed up was performed through electronic medical records or telephone interviews until patient rehospitalization for heart failure or discharge for one year.

Read the detailed description

The included patients who diagnosed with HFpEF and healthy volunteers at the First Affiliated Hospital of Shandong First Medical University from December 20, 2023 to December 20, 2026. Routine clinical and echocardiographic data, two-dimensional strain parameters and IVP of the study subjects were obtained:

  1. The echocardiographic examination was performed using a GE Vivid E95 ultrasound machine, and images were acquired with the patient in left lateral decubitus using a 3.5-5 MHz transducer at a depth of 16 cm. ECG was recorded, and 3 consecutive cardiac cycles of each view were recorded during quiet breathing at 50-80 frames/sec. All patients were subjected to conventional transthoracic echocardiography, Speckle tracking echocardiography and IVP. All measurements were taken following the American Society of Echocardiography (ASE) recommendations.
  2. Left atrial and left ventricle strain analysis was obtained using automated speckle tracking software. The regions of interest were generated automatically and left atrial endocardial border was manually adjusted when required. Left atrial phases definition and left atrial strain values were measured from the Left atrial longitudinal strain curve according to the European Association of Cardiovascular Imaging (EACVI)/American society of echocardiography (ASE) guidelines. Global left ventricle strain was evaluated, and the software automatically traced the contour of the endocardium at apical three, four and two-chamber views.
  3. For IVP analysis, we first entered Q-analysis and then used the curved anatomic M-mode to trace the left ventricle myocardium to reconstruct the axial tissue velocity maps. The tissue velocity map scale was adjusted to create velocity aliasing to better illustrate the is velocity wave front that propagated in the myocardium during end-diastole induced by atrial contraction. Sweep speed was adjusted to maximum, and the slope of the is velocity wave was measured as the propagation speed of the intrinsic wave. The average wave velocity was calculated using all measurements from all six myocardial walls using the three apical views.
  4. At the same time, the general clinical data, demographic characteristics, electrocardiogram, coronary artery CTA, carotid ultrasound, and laboratory results include brain natriuretic peptide (BNP), uric acid (UA), soluble growth stimulating expression gene 2 protein (sST2), growth differentiation factor 15(GDF-15), Galectin-3 (Galectin-3) were obtained through electronic health record.
  5. Clinical follow-up was performed every 6 months after discharge by phone and by electronic health record review until heart failure readmission or one year after discharge. Heart failure rehospitalization was defined as any rehospitalization during which HF was listed as one primary diagnosis based on typical heart failure symptoms, signs and increased B-type natriuretic peptide levels for which intravenous diuretics or increased dose of loop diuretics were needed in clinic.
03

Conditions studied

  • Heart Failure With Preserved Ejection Fraction

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients who diagnosed with HFpEF according to the 2022 AHA/ACC/HFSA Guidelines for Heart Failure Management.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Meet the diagnostic criteria for HFpEF in the 2022 AHA/ACC/HFSA Guidelines for Heart Failure Management:

  • Present with signs and symptoms of heart failure;
  • ≥50%;
  • There is at least one additional criterion: Increased BNP (BNP≥35pg/ml, NT-pro BNP>125pg/ml) and resting echocardiography measured E/e' ≥ 15; Stress echocardiography determined E/e' ≥ 15; Cardiac catheterization at rest, PCWP ≥ 15 mmHg or LVEDP ≥ 16 mmHg; The PCWP at peak exercise was ≥ 25 mmHg.

Exclusion criteria

Exclusion Criteria:

  • Acute coronary syndrome, acute heart failure or coronary revascularization in three months;
  • HFimpEF, cardiomyopathy, severe valvular heart disease, arrhythmia;
  • Thyroid dysfunction, pulmonary hypertension, past or current pulmonary embolism, severe , /renal failure (less than 30) ml/min);
  • Poor echocardiogram image quality.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
438 participants (estimated)
Patient registry
No

Groups and cohorts

  • HFpEF

    Patients who diagnosed with heart failure with preserved ejection fraction based on symptoms, serum biomarker and test according to 2022 AHA/ACC/HFSA Guidelines for Heart Failure Management at the First Affiliated Hospital of Shandong First Medical University from December 20, 2023 to December 20, 2026.

    Diagnostic Test: Echocardiography examination

  • Control

    Healthy volunteers with no history of heart disease who matched for age, sex, and risk factors with HFpEF group.

    Diagnostic Test: Echocardiography examination

Interventions

  • Diagnostic testEchocardiography examination

    Echocardiography examination and software post-processing analysis was performed to obtain parameters of conventional echocardiography, left atrial and left ventricle strain, and IVP.

06

What researchers measure

Primary outcomes

  1. IVP

    The propagating wave velocity along longitudinal tissue motion direction is referred to as the Intrinsic Velocity Propagation (IVP). It is generated through the dynamic nature of the heart and allows quantification in all LV segments. It is possible that this wave is related to tissue stiffness and has a radial component.

    Time frame: After recruiting, IVP collected through software post-processing analysis will be assessed and reported up to 8 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 36 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2023
First posted
Jan 9, 2024
StartActual
Dec 20, 2023
Primary completionEst.
Dec 20, 2026
CompletionEst.
Dec 20, 2027
Last update
Jan 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06196086
Lead sponsor
Haiyan Wang
Responsible party
Haiyan Wang (Director, Qianfoshan Hospital) — Sponsor-investigator
First posted
Jan 9, 2024
Start date
Dec 20, 2023
Primary completion
Dec 20, 2026 (estimated)
Completion
Dec 20, 2027 (estimated)
Last update
Jan 9, 2024

Study contacts

Haiyan Wang, MD
Contact
wanghaiyan96@126.com
13583184107
Haiyan Wang
principal investigator · The First Affiliated Hospital of Shandong First Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion